Disc Medicine Posts Phase 3 Results as Merck KGaA Buys Silence
Biotech stocks rose following positive trial data and a major acquisition announcement.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Is now a good time for individual investors to enter volatile biotech stocks after positive news?
Disc Medicine reported that its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in a study of 183 patients. Simultaneously, Merck KGaA agreed to acquire Silence Therapeutics in a deal valued at $1.3 billion.
Why it matters
These developments highlight significant progress in targeting red blood cell biology and iron-metabolism disorders. The trial outcomes and corporate consolidation reflect ongoing investment and scientific activity within the rare blood-disease sector.
The APOLLO trial enrolled 183 patients treated with 60 mg of oral bitopertin or placebo over six months. The drug demonstrated a 41.4% reduction in metal-free protoporphyrin IX levels and added 12.2 hours of monthly pain-free light exposure.
The players
Disc Medicine
This clinical-stage biopharmaceutical company focuses on developing treatments for hematologic and iron-metabolism disorders.
Silence Therapeutics
This biotechnology firm specializes in developing gene-silencing therapies using proprietary messenger RNA technology.
Merck KGaA
Headquartered in Germany, this multinational science and technology company operates in the healthcare, life science, and electronics sectors.
Agios Pharmaceuticals
This pharmaceutical company is currently awaiting an FDA regulatory decision regarding a supplemental application for a sickle cell disease treatment.
The details
Disc Medicine plans to resubmit its New Drug Application by the end of 2026, while the acquisition of Silence Therapeutics is set to proceed through a U.K. scheme of arrangement. The takeover price of $20.00 per American Depositary Share represents a 130% premium over the October 16 closing price.
Timeline
October 19, 2026: Disc Medicine announced trial results and Silence Therapeutics announced the acquisition.
October 20, 2026: Biotech stocks rose following the announced industry developments.
November 1, 2026: PDUFA date for Agios Pharmaceuticals' supplemental application.
End of 2026: Expected timeline for Disc Medicine to resubmit its New Drug Application.
First quarter of 2027: Expected closing of the Silence Therapeutics acquisition.
The Tech Race
These developments track with the broader competitive arms race in hematology drug development as firms align with the FDA's PDUFA review process. This strategic movement highlights how biotech entities use clinical trial successes to bolster their valuations before potential acquisition.
For investors and industry followers, these developments signal potential shifts in portfolio value and future treatment options for blood-disorder patients. The upcoming regulatory milestones could directly influence the market availability of next-generation therapies.
The takeaway
The recent surge in biotech stock performance underscores how successful Phase 3 trial data can trigger rapid market consolidation. Investors should monitor upcoming regulatory dates as these events frequently determine the commercial viability of emerging medical technologies.
What happens next
Agios Pharmaceuticals has a scheduled PDUFA date for its supplemental application on November 1, 2026. The acquisition of Silence Therapeutics by Merck KGaA is expected to close in the first quarter of 2027.
Further reading
For more information on the evolving landscape of drug development, visit the Biotech section.
Source note: This article includes information reported by Belleville Intelligencer.
Live Poll
Is now a good time for individual investors to enter volatile biotech stocks after positive news?
